Alpha-toxin-elicited CX 3 CL1 release in Staphylococcus aureus pneumonia impairs bactericidal function of human monocytes
mBio · 12.11.2025 · 16 (11)
DOI: 10.1128/mbio.02689-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, erschienen am 12.11.2025. Verfasst von Srikanth Mairpady Shambat und 20 weiteren Autor:innen. Beteiligte Einrichtung: Center for Infectious Medicine, Department of Medicine, ANA Futura, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden. Hauptthemen laut MEDLINE: Bacterial Toxins, Monocytes, Staphylococcus aureus, Chemokine CX3CL1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, NordForsk, Clinical Research Priority Program (CRPP) of the University of Zurich.
Abstract (Originalsprache)
Staphylococcus aureus is an important human pathogen causing severe invasive infections. Pathogenesis is attributed to a wide array of virulence factors, including several potent exotoxins such as the pore-forming α-toxin. In this study, we found that patients with S. aureus respiratory tract infections had elevated CX 3 CL1 levels in airway fluid and plasma. Using human-organotypic lung models, we observed that stimulation of lung epithelium with α-toxin induces an intensified CX 3 CL1 expression apically in the epithelium as well as the release of CX 3 CL1. Blocking α-toxin or ADAM10 activity in organotypic lung using an α-toxin-blocking antibody or a specific ADAM10 inhibitor confirmed their role in modulating CX 3 CL1 cleavage and release. Analyses of CD14 + human monocytes in combination with a CX 3 CR1 inhibitor revealed that α-toxin-mediated CX 3 CL1 release induces CX 3 CL1-dependent chemotaxis. In line with these data, lung tissue from patients with S. aureus respiratory tract infection showed elevated CX 3 CL1 and CD14 staining as compared with tissue from patients with non-infectious lung diseases. Functional studies of monocytes showed that CX 3 CL1 released by lung models resulted in upregulated CD83 and downregulated CD86, as well as impaired killing of phagocytosed S. aureus . Furthermore, stimulation of monocytes with soluble CX 3 CL1 hampered their reactive-oxygen and nitric-oxide production. Taken together our data show that S. aureus triggers the release of lung epithelial CX 3 CL1, and we identify an immunomodulatory effect of α-toxin involving its cytotoxic and ADAM10-interacting properties, inducing CX 3 CL1 release leading to impaired monocyte effector function. IMPORTANCE Exotoxins are essential virulence factors for the pathobiont S. aureus and contribute toward severe invasive infections such as pneumonia. S. aureus α-toxin is a pore-forming exotoxin that causes host cell lysis and severe lung pathology. We found that α-toxin drives the release of membrane-bound chemokine CX 3 CL1 by involving ADAM10-mediated proteolytic activity. Furthermore, the release of CX 3 CL1 modulated immune responses locally, as demonstrated by enhanced monocyte migration and reduced capacity of monocytes to kill ingested bacteria. CX 3 CL1-induced reduction in bacterial killing coincided with impaired production of reactive oxygen and nitric oxide species. This reveals a novel mechanism in the pathogenesis of S. aureus lung infections involving α-toxin-induced release of CX 3 CL1, leading to impaired bacterial killing by monocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Infectious Medicine, Department of Medicine, ANA Futura, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden.
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
- Harvard Medical School and Brigham and Women's Hospital Ann Romney Center for Neurologic Diseases, Boston, Massachusetts, USA.
- Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
- Vaccines and Immune Therapies, AstraZeneca, Gaithersburg, Maryland, USA.
- Department of Respiratory, Inflammation and Autoimmunity, AstraZeneca, Gothenburg, Sweden.
ORCID-Profile: Srikanth Mairpady Shambat, Markus Huemer, Alejandro Gómez-Mejia, Kristoffer Strålin, Annelies S Zinkernagel, Anna Norrby-Teglund, Mattias Svensson
Förderung
- Vetenskapsrådet
- NordForsk
- Clinical Research Priority Program (CRPP) of the University of Zurich
- Karolinska Institutet
- Svenska Sällskapet för Medicinsk Forskning
- Uniscientia Stiftung
- Barncancerfonden
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Mairpady Shambat, S., Chen, P., Barilla, R. M., Huemer, M., Snäll, J., Welin, A., Cohen, T. S., Takahashi, V., Berry, S. B., Gómez-Mejia, A., Schweizer, T. A., Cunoosamy, D. M., Cajander, S., Lourda, M., Özenci, V., Maggio, E. M., Schüpbach, R. A., Strålin, K., Zinkernagel, A. S., …, & Svensson, M. (2025). Alpha-toxin-elicited CX 3 CL1 release in Staphylococcus aureus pneumonia impairs bactericidal function of human monocytes. mBio, 16(11). https://doi.org/10.1128/mbio.02689-25
Vancouver
Mairpady Shambat S, Chen P, Barilla RM, Huemer M, Snäll J, Welin A, et al. Alpha-toxin-elicited CX 3 CL1 release in Staphylococcus aureus pneumonia impairs bactericidal function of human monocytes. mBio. 2025;16(11). doi:10.1128/mbio.02689-25
BibTeX
@article{MairpadyShambat2025,
author = {Mairpady Shambat, Srikanth and Chen, Puran and Barilla, Rocky M and Huemer, Markus and Snäll, Johanna and Welin, Amanda and Cohen, Taylor S and Takahashi, Virginia and Berry, Samuel B and Gómez-Mejia, Alejandro and Schweizer, Tiziano A and Cunoosamy, Danen M and Cajander, Sara and Lourda, Magda and Özenci, Volkan and Maggio, Ewerton Marques and Schüpbach, Reto A and Strålin, Kristoffer and Zinkernagel, Annelies S and Norrby-Teglund, Anna and Svensson, Mattias},
title = {Alpha-toxin-elicited CX 3 CL1 release in Staphylococcus aureus pneumonia impairs bactericidal function of human monocytes},
journal = {mBio},
year = {2025},
volume = {16},
number = {11},
doi = {10.1128/mbio.02689-25}
}
EUVIMED